Le Lézard
Classified in: Health
Subject: FDA

United Imaging Healthcare uPMR 790 HD TOF PET/MR Cleared by FDA


HOUSTON, May 8, 2019 /PRNewswire/ -- United Imaging Healthcare (UIH), an international leader in advanced medical imaging and radiotherapy equipment, announced the U.S. Food and Drug Administration (FDA) clearance of the uPMR 790 HD TOF PET/MR. uPMR 790 redefines clinical routine imaging for PET/MR with the capability to scan a whole body within 20 minutes, balancing patient comfort with high-quality imaging. With the uPMR 790, United Imaging Healthcare demonstrates its commitment to advance precision medicine in the fields of neurology, oncology, and cardiology.

The next generation platform of the uPMR 790 delivers state-of-the-art PET and MR performance that rises above the current technology standards. The HD TOF PET platform is based on digital silicon photomultipliers (SiPMs) and lutetium-yttrium oxyorthosilicate (LYSO) crystals, offering a 2.8 mm NEMA PET spatial resolution with time-of-flight (TOF) technology and a large 32cm axial field-of-view. When this technology is combined with compressed sensing for whole body isotropic 3D MR imaging, it results in fast simultaneous whole-body PET and MR scans. This technology redefines PET/MR imaging by offering clinicians high isotropic spatial resolution to visualize small lesions while accelerating acquisition times to maximize patient comfort.

uPMR 790 also offers cutting-edge imaging for research, including theranostics and neuroscience which benefit from an increase in sensitivity, resolution, and coverage. United Imaging Healthcare's uSync Research platform enables additional opportunities for research in areas such as simultaneous tracking of PET and MRI tracers, real-time cardiac PET/MR, functional neurological PET/MR, and multi-parametric radiometrics.

"The uPMR 790 sets a new standard for simultaneous PET and MR performance by not only enhancing the precision and resolution of scans, but by also dramatically changing the patient experience," said Jeffrey M. Bundy, Ph.D., Chief Executive Officer of UIH Solutions. "Today's announcement again delivers on our mission to embed breakthrough innovation across our portfolio. The uPMR is yet another proof point of our commitment to provide more patients in the United States with access to advanced technology and higher standards of care."

ABOUT UIH
United Imaging Healthcare Technology Group Co., Ltd. (UIH) develops and produces a full portfolio of advanced medical imaging and radiotherapy equipment and offers medical IT and intelligent solutions. Founded in 2011 and headquartered in Shanghai, the company has subsidiaries and R&D centers across China, US, and other parts of the world. UIH's vision is to lead healthcare innovation. Through innovation, UIH aims to contribute to bringing equal healthcare for all people worldwide.
To learn more, visit https://www.united-imaging.com.

SOURCE United Imaging Healthcare Co., Ltd.


These press releases may also interest you

at 01:15
STELFONTA® (tigilanol tiglate) approved by the European Medicines Agency (EMA), making it the first pharmaceutical treatment available for all grades of canine non-metastatic mast cell tumours (MCT)[1] The approval marks the first registration of...

at 01:00
Osmo Pocket is DJI's most portable 3-axis stabilized gimbal camera, the perfect tool for capturing every moment of life, from the ordinary to the extraordinary. It packs state-of-the art technology into a small and lightweight body-frame that fits in...

at 00:47
KT Corporation (KRX: 030200; NYSE: KT), Korea's largest telecommunications company, and the Samsung Medical Center (SMC) announced last week that they have jointly developed an...

19 jan 2020
Balticgruppen Bio, the Umeå based Biotech company focused on development of AMPK activator compounds, operating under the trademark Betagenon, has closed a funding round with China based asset management firm Ivy Capital granting the company 3 MUSD...

19 jan 2020
Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, Republic of Korea, announced that the Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) has been cleared on...

19 jan 2020
End of Life Care for Cancer Cancer is one of the most serious modern-day diseases, and its prevalence has increased drastically over the past years. This increased prevalence can be owed to multiple lifestyle factors. Many new treatments have been...



News published on 8 may 2019 at 08:00 and distributed by: